Home » Topics » BioWorld Science

BioWorld Science
RSS

AIDS Research Highlights (July 7-12, Vancouver)

July 12, 1996

Positive efficacy/safety profile for liposomal formulation of DaunoXome

July 12, 1996

3TC/AZT combination phase II/III trial results published

July 12, 1996

Acemannan ineffective on surrogate markers

July 12, 1996

New formulaton of Videx launched in Canada

July 12, 1996

Zerit reaches Canadian market

July 12, 1996

Vion issued U.S. patent regarding hepatitis B treatment

July 12, 1996

Abbott presents HIV RNA-reducing drug combinations

July 12, 1996

Novel antibacterial agents from Pharmacia & Upjohn

July 12, 1996

Erythromycin derivatives useful for infection treatment

July 12, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.